Archive photo: Ian Furst, CC BY-SA 4.0. Illustrative.
Adults with psoriatic arthritis, a disease that can leave joints painful, swollen and stiff, have another treatment option, according to Sun Pharma. The drugmaker said Friday that the U.S. Food and Drug Administration approved Ilumya for adults with active disease, extending a medicine already used for plaque psoriasis into joint disease.
Sun Pharma’s October 30 announcement says Ilumya, also called tildrakizumab-asmn, must be administered by a healthcare provider. This is not a new self-injection product, and approval does not mean the disease has been cured.
From skin symptoms to joint disease
Sun Pharma is a pharmaceutical company that develops and sells prescription medicines. Ilumya is one of its branded treatments. It blocks an immune-system signal called interleukin-23, or IL-23, that is involved in inflammation.
The medicine was first approved in the United States in 2018 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic treatment or light therapy. The new use described by the company is for adults with active psoriatic arthritis, which can affect joints and the places where tendons and ligaments attach to bones.
The practical difference is where treatment happens. Because a healthcare professional gives Ilumya, the company says it may be an option for suitable adults who cannot give themselves injections or may benefit from regular in-office care. Whether it is appropriate for a particular person remains a decision for the patient and clinician.
What evidence the company disclosed
Sun Pharma said the approval was supported by its Phase 3 INSPIRE-1 and INSPIRE-2 studies. It described them as 52-week, randomized, double-blind studies comparing Ilumya with a placebo in adults with active psoriatic arthritis.
The announcement did not provide numerical results showing how many patients improved on the main efficacy measures. Those figures should not be guessed, and this announcement alone does not establish that Ilumya is better than other available treatments.
The approval is reported here as the company’s announcement. At the time of review, the prescribing-information document linked by the release and the FDA label located for this article were both revised in July 2026 and still listed plaque psoriasis rather than the newly announced arthritis use. They do not independently verify the updated indication.
Safety and access still matter
Sun Pharma warned that Ilumya may increase the risk of infection and said patients should be evaluated for tuberculosis before treatment. The company also says live vaccines should be avoided during treatment. Its release lists upper respiratory tract infections and COVID-19 among the most common adverse reactions in the psoriatic-arthritis studies.
The announcement does not establish what an individual patient’s insurance will cover or what that patient will pay. An expanded approved use and affordable access are separate questions.
For patients, the news is an additional provider-administered treatment option, according to the company. The useful next questions are whether that option fits their disease, prior treatment, safety risks and coverage, rather than whether an approval headline promises a cure.
JBizNews Desk | HEALTH
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
